BioNTech SE Sponsored ADR $BNTX Shares Sold by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. cut its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 7.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,484,599 shares of the company’s stock after selling 349,043 shares during the period. T. Rowe Price Investment Management Inc.’s holdings in BioNTech were worth $426,934,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Larson Financial Group LLC raised its holdings in shares of BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the last quarter. EFG International AG purchased a new position in BioNTech in the 4th quarter worth $29,000. Caitong International Asset Management Co. Ltd lifted its position in BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after acquiring an additional 260 shares during the period. Huntington National Bank grew its stake in BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after purchasing an additional 305 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Insider Activity

In related news, COO Sierk Poetting sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the completion of the sale, the chief operating officer directly owned 399,387 shares in the company, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BNTX. Morgan Stanley upped their target price on BioNTech from $125.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. HC Wainwright reaffirmed a “buy” rating and issued a $130.00 price objective on shares of BioNTech in a report on Monday, April 27th. Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Berenberg Bank lowered their price target on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a report on Wednesday, April 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $129.56.

BioNTech Price Performance

BioNTech stock opened at $90.89 on Friday. The stock has a market capitalization of $22.98 billion, a P/E ratio of -15.46 and a beta of 1.32. The company’s fifty day moving average price is $94.58 and its 200 day moving average price is $98.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The company had revenue of $1.06 billion during the quarter. As a group, equities research analysts anticipate that BioNTech SE Sponsored ADR will post -5.03 earnings per share for the current fiscal year.

BioNTech declared that its board has authorized a share repurchase program on Thursday, May 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 4.2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.